Medical practitioners who have had the experience of cultivating cells may also have the following experience: cells raised in vitro, the degree of malignancy is even higher, raised on a certain number of generations, (but also have to be careful to wait for the person) the cells can no longer be raised; why is it that tumor cells, which are very powerful and a little bit scary in vivo, can not be eradicated no matter what kind of methods, and are also so weak in vitro? If the conditions in the body can be like in vitro culture, we actually do not need to develop new drugs, the current drugs are already enough, just one is enough to kill cancer cells. The question is why is it different once the drug is in the body? What kind of magic can cancer cells do in the body that allows them to escape this fate? We all know that cancer cells can proliferate, infiltrate and metastasize indefinitely, what is its driving force? What we can see under the pathological section is that a group of cancer cells leave the tissue in situ and “leave their home country” to rush to other places. Cancer cells are incompletely differentiated cells, which means that its growth process is interrupted for some reasons, the old cells are still immature, and the new cells are constantly proliferating and dividing, which is “deteriorating” for human beings, but it is indeed “evolutionary” favorable for itself, which is conducive to its better growth and “territory expansion”. This “deterioration” of human beings is beneficial to their own “evolution”, which is conducive to their better growth and “expansion of territory”. It should be said that this is also the “survival of the fittest” needs. Chinese medicine emphasizes balance and the unity of man and nature. In fact, from a biological point of view, human beings are also members of the natural world. Disease and health are the result of the interaction between the body’s resistance and disease-causing factors, and the two are mutually reinforcing. The key lies in how we maintain a balanced state. Tumor cells themselves are part of the body’s cells, but it is the disorder of the body’s control system that leads to the overgrowth of these cells. What we ask is that these cells return to their original state of proliferation. In fact, this is a balance. But we should seek this balance, and can not be emphasized to take all kinds of methods to kill these overgrowth of cells (in fact, it is also in the killing of the body cells, but they have mutated). Nowadays, many treatments: surgery, chemotherapy, radiotherapy, immunotherapy, physiotherapy, biotherapy, Chinese medicine and so on, have not been able to cure the tumor completely. Then should we switch our treatment direction? Statistically, due to advances in ultrasound technology, 80% of women suffer from uterine fibroids, but the vast majority of uterine fibroids do not need to be treated at all and live their entire lives in peace with their owners, many of which eventually die out naturally. The same goes for intrahepatic bile duct stones. For tumors, if we no longer fear them, but use the least disturbing means for the organism to control the tumor within a certain range, so that it can coexist with the organism and live in peace with it, this viewpoint of surviving with tumors is also a direction. At present, our tumor treatment seems to be a “big siege”. We all know that there are three major methods of tumor treatment: surgery, chemotherapy, radiotherapy, and other biological treatment, physical therapy, Chinese medicine and so on. But how should we operate for a specific patient? In recent years, with the advancement of technology, chemotherapeutic drugs have been greatly improved, which makes a considerable part of tumors get better chemotherapeutic effect, better quality of life and longer survival period. In the past 30 years, especially in the past 15 years, there has been a rapid development in the research of chemotherapy and related medications in medical oncology. Taking NSCLC as an example, the clinical application of third-generation chemotherapeutic agents has clearly improved the median survival of the patients, while it is difficult to evaluate whether the application of the first-generation chemotherapeutic agents is beneficial to the majority of NSCLC patients. The current advances in chemotherapy have not been revolutionary enough to be called so because the number of diseases it can potentially treat has not increased. Ten years ago, the number of common tumors that could be cured with chemotherapy as the main treatment, such as small-cell lung cancer, malignant lymphoma, germline tumors such as spermatogonial tumors, and some hematological tumors, is still the same today (long-term tumor-free survival). Previously, the survival period of effective cases, such as non-small cell lung cancer, breast cancer, ovarian cancer, etc., has been lengthened, the immediate therapeutic effect has been improved, and the chances of cure have been increased in some cases through the participation of chemotherapy, such as neoadjuvant chemotherapy. In some cases, chemotherapy has increased the chance of cure, such as neoadjuvant chemotherapy. In some cases, new therapeutic drugs, such as targeted therapies, have been developed for those cases where the original chemotherapy was ineffective, but they do not cure the tumor. Our surgical methods are constantly improving, from being afraid to do it but small at the beginning, to expanding radical treatment later on, and then to minimally invasive surgery nowadays, all of which reflect the change of people’s concepts of treatment and survival. Radiotherapy has been used as a no solution for most tumors. And with the improvement of technology, with the application of advanced technology such as conformal radiotherapy, its efficacy is also gradually improved, and its side effects are also gradually reduced, however, what is the result? There is no cure for malignant tumors. Problems of current tumor treatment 1, drug resistance, how to screen out the chemotherapy drugs that are sensitive to tumors? Tumor multidrug resistance problem is an important cause of chemotherapy failure, which involves a variety of mechanisms, one of which is the mdr-1 gene and P-gp mechanism, the latter is a protein encoded by mdr-1, the role of which is equivalent to the drug output pump, which can pump intracellular drugs out of the cell, thus leading to a reduction in the concentration of drugs in the tumor cells, resulting in drug resistance. When it comes to typical MDR associated with P-gp, drugs of natural origin such as ADM and Vincristine analogs are prone to cause typical MDR, and the traditional understanding of drugs of natural origin is that they generally cannot cause drug resistance. In Chinese medicine, patients are given prescriptions and medicines through observation, diagnosis and treatment. It is possible that different patients have the same basic prescription, but with different additions, subtractions and dosages of medicinal flavors, which is comparable to the current individualized medication. Different patients should not take one big pot of boiled medicine. Drugs of natural origin such as ADM, are extracted and cannot be fully compared with traditional herbal medicines, their MDR, is explained by modern medical research. Drug combination chemotherapy is mostly used to address the problem of drug resistance. The principles are hematologic toxicity, single-drug effectiveness, different mechanisms of action and resistance mechanisms, and so on. 2, toxic side effects, serious toxic side effects limit the application of chemotherapeutic drugs. It is important to support the application of drugs. 3.Price and the development of molecular targeting drugs have brought new hope to tumor patients, but they are expensive, and it is worthwhile to study how to maximize the benefit of patients from them. 4. Problem of cooperation with other departments. It is an old problem that many departments rush to give chemotherapy to tumor patients, and many doctors do not understand the toxicity and side effects of chemotherapeutic drugs and then blindly go on chemotherapy, which is irresponsible to the patients and dangerous to the doctors themselves. As a doctor, in the medical activities, we must shoulder the responsibility of attacking and exploring various difficult and complicated diseases, and we are the leader of the whole treatment process of the patients, and we are responsible for the “leading responsibility” of the “action” of the patient’s organism to rediscover the equilibrium. We can not follow the books, according to the dogma to the patient “announced the terms”, but should give each patient to find a best recovery program, to help patients from the disease early recovery. I advocate the establishment of a sound oncology treatment center with a “patient-centered system”. For each patient, the oncology center will organize a consultation and discussion among physicians of relevant departments to formulate a corresponding treatment plan, and the attending physician will make the final decision and be responsible for the implementation of the whole plan. Just like the single-patient management model firstly advocated by Prof. Wu Yilong of Sun Yat-sen University of Medical Sciences in China, the new model integrating surgery, chemotherapy, radiotherapy, biotherapy and various new technologies forms a group force to deal with each specific patient, which institutionally guarantees the smooth implementation of multidisciplinary integrated treatment, and at the same time ensures that the patient can get the best and most comfortable treatment and psychological care. The package of treatment plans that take into account the therapeutic effect and quality of life for each patient forms the maximum therapeutic effect in terms of single disease treatment in the Oncology Center. This approach allows the patient to receive the maximum and best treatment, and is a gradual transformation of our doctors into humanistic doctors. In addition, we also advocate evidence-based medicine and multidisciplinary integrated treatment, promote the study of clinical randomized trials, and establish epidemiological surveys of single diseases, design relevant electronic medical record system, with the call, long-term follow-up, and timely statistical analysis. Provide evidence-based basis for our clinical work. I believe that under the joint efforts of all colleagues, the problem of homework tumor is not a myth.